WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong
· Delayed Price · Currency is HKD 26.80
-0.95 (-3.42%)
Mar 28, 2025, 4:08 PM HKT
WuXi Biologics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 18,675 | 17,034 | 15,269 | 10,290 | 5,612 | Upgrade
|
| Revenue Growth (YoY) | 9.63% | 11.56% | 48.38% | 83.34% | 40.88% | Upgrade
|
| Cost of Revenue | 11,025 | 10,206 | 8,545 | 5,461 | 3,079 | Upgrade
|
| Gross Profit | 7,651 | 6,828 | 6,724 | 4,829 | 2,533 | Upgrade
|
| Selling, General & Admin | 2,147 | 1,789 | 1,433 | 1,001 | 605.85 | Upgrade
|
| Research & Development | 766.44 | 785.82 | 682.82 | 501.58 | 303.73 | Upgrade
|
| Other Operating Expenses | - | 23.47 | -1.49 | 24.29 | 4.95 | Upgrade
|
| Operating Expenses | 3,065 | 2,895 | 2,374 | 1,659 | 1,031 | Upgrade
|
| Operating Income | 4,585 | 3,933 | 4,350 | 3,170 | 1,502 | Upgrade
|
| Interest Expense | -157.59 | -158.49 | -64.38 | -39.19 | -42.73 | Upgrade
|
| Interest & Investment Income | 351.54 | 219.18 | 115.79 | 58.03 | 80.86 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | 2.63 | Upgrade
|
| Currency Exchange Gain (Loss) | -45.22 | 46.73 | 417.2 | -32.58 | -91.3 | Upgrade
|
| Other Non Operating Income (Expenses) | 191.9 | 173.38 | 159.56 | 171.36 | 142.54 | Upgrade
|
| EBT Excluding Unusual Items | 4,926 | 4,214 | 4,978 | 3,328 | 1,594 | Upgrade
|
| Gain (Loss) on Sale of Investments | -91.72 | 13.83 | 379.44 | 665.44 | 371.44 | Upgrade
|
| Other Unusual Items | - | -53.58 | - | - | - | Upgrade
|
| Pretax Income | 4,834 | 4,174 | 5,358 | 3,993 | 1,966 | Upgrade
|
| Income Tax Expense | 889.03 | 603.18 | 807.87 | 484.54 | 273.07 | Upgrade
|
| Earnings From Continuing Operations | 3,945 | 3,571 | 4,550 | 3,509 | 1,693 | Upgrade
|
| Minority Interest in Earnings | -589.29 | -170.9 | -129.62 | -120.1 | -3.81 | Upgrade
|
| Net Income | 3,356 | 3,400 | 4,420 | 3,388 | 1,689 | Upgrade
|
| Net Income to Common | 3,356 | 3,400 | 4,420 | 3,388 | 1,689 | Upgrade
|
| Net Income Growth | -1.28% | -23.09% | 30.45% | 100.63% | 66.59% | Upgrade
|
| Shares Outstanding (Basic) | 4,082 | 4,164 | 4,173 | 4,174 | 3,953 | Upgrade
|
| Shares Outstanding (Diluted) | 4,227 | 4,349 | 4,376 | 4,422 | 4,209 | Upgrade
|
| Shares Change (YoY) | -2.80% | -0.62% | -1.04% | 5.05% | 5.30% | Upgrade
|
| EPS (Basic) | 0.82 | 0.82 | 1.06 | 0.81 | 0.43 | Upgrade
|
| EPS (Diluted) | 0.78 | 0.77 | 1.01 | 0.77 | 0.40 | Upgrade
|
| EPS Growth | 1.55% | -23.50% | 31.17% | 92.50% | 60.00% | Upgrade
|
| Free Cash Flow | - | 622.14 | -326.72 | -3,077 | -4,144 | Upgrade
|
| Free Cash Flow Per Share | - | 0.14 | -0.07 | -0.70 | -0.98 | Upgrade
|
| Gross Margin | 40.97% | 40.08% | 44.04% | 46.93% | 45.13% | Upgrade
|
| Operating Margin | 24.55% | 23.09% | 28.49% | 30.81% | 26.77% | Upgrade
|
| Profit Margin | 17.97% | 19.96% | 28.95% | 32.93% | 30.09% | Upgrade
|
| Free Cash Flow Margin | - | 3.65% | -2.14% | -29.90% | -73.83% | Upgrade
|
| EBITDA | 5,581 | 4,928 | 5,069 | 3,622 | 1,771 | Upgrade
|
| EBITDA Margin | 29.88% | 28.93% | 33.20% | 35.20% | 31.56% | Upgrade
|
| D&A For EBITDA | 995.46 | 995.46 | 718.63 | 452.24 | 268.92 | Upgrade
|
| EBIT | 4,585 | 3,933 | 4,350 | 3,170 | 1,502 | Upgrade
|
| EBIT Margin | 24.55% | 23.09% | 28.49% | 30.81% | 26.77% | Upgrade
|
| Effective Tax Rate | 18.39% | 14.45% | 15.08% | 12.13% | 13.89% | Upgrade
|
Updated Sep 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.